Ortho Regenerative Technologies Inc
Ortho-R Receives FDA Regulatory Designation and Jurisdictional Assignment
Ortho-R is designated as a Drug/Biologic combination product, by the FDA Office for Combination Products. The jurisdictional...
Ortho Regenerative Technologies Inc
Ortho RTi Confirms Timeline to Initiate Human Clinical Program After Meeting with the FDA
As a result, the Company is in the position to submit its Investigational New Drug while completing its pivotal study and confirms the timeline to initiate human clinical program by year end.
Ortho Regenerative Technologies Inc
Ortho RTi Announces Results of Two Key Scientific Studies
2/4/19: Both key scientific studies validate its product's ability to improve the repair of two distinct joint tissues, the rotator cuff tendon and articular cartilage.
Ortho Regenerative Technologies Inc
Data from Ortho-R Pilot Study in Rotator Cuff Repair is Compelling
4/2/18: Conducted by researchers from Montreal's prestigious École Polytechnique, the pilot dose escalation study used MR imaging outcomes, read by two blinded experts at 3 intervals, to compare the results of Ortho-R versus standard of care in a non-clinical rotator cuff injury model in sheep.
